Market Overview

Allianz's Analyst Likes Biogen Idec Inc, Celgene Corporation & Gilead

Related GILD
Jefferies Says Gilead's 4997 Data Is Impressive, Underappreciated
Exclusive: SunTrust Top Analysts Explain Fatty Liver Diseases, Galmed's Potential In The Space
6 Undervalued Stocks Trading Below the Peter Lynch Value (GuruFocus)
Related BIIB
Earnings Scheduled For October 26, 2016
25 Stocks Which Rallied Four Days, Then Sold Off On Friday
Biogen (BIIB) Q3 2016 Results - Earnings Call Transcript (Seeking Alpha)

John Schroer of Allianz Global Investors spoke on CNBC's Fast Money about the biotech stocks he likes.

He said that his first pick would be Biogen Idec Inc (NASDAQ: BIIB), which is a leading company in the multiple sclerosis space. He thinks that the company will have 20 to 25 percent earnings growth over the next three years, and it has a valuation of 25 times earnings.

The biotech stock sold off on Friday on the news about potential pricing pressure on Gilead's (NASDAQ: GILD) hepatitis C medicine. Schroer thinks that Gilead is a great stock, trading at 11 times earnings, with a strong growth potential that could easily trade at $200 billion market capitalization.

Celgene Corporation (NASDAQ: CELG) has also found its place on the list of stocks in the biotech space that John Schroer would buy. Celgene fell 0.15 percent on Friday, and it closed at $93.79.

Posted-In: Allianz Global Investors Biotech Stocks John SchroerCNBC Media


Related Articles (BIIB + CELG)

View Comments and Join the Discussion!